Proprietary model informs targeted sales and marketing strategies with feedback loop that
augments precision and impact of targeting and engagement
Citius Oncology, Inc., the oncology-focused subsidiary of Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, announced that it has deployed an innovative AI platform to support its commercial team with advanced data analytics and insights ahead of the anticipated launch of LYMPHIR, a novel therapy for cutaneous T-cell lymphoma. The platform was developed to strengthen decision-making, refine targeting, and enhance the efficiency of its salesforce by supporting timely, data-informed engagement with healthcare providers.
Health Technology Insights: Angle Health and PerfectQuote Launch Real-Time Rate Quotes
The proprietary system uses company-defined criteria to identify patterns in treatment and diagnosis, enabling our commercial team to immediately target prescribers whose patients may benefit from LYMPHIR. The platform uses machine learning to continuously refine its ability to identify potential LYMPHIR candidates and allow the commercial team to support more informed patient care.
Health Technology Insights: Saigon Technology Powers AI Beyond SaaS Limits
“We look forward to having this innovative AI platform amplify the precision and impact of our experienced commercial and marketing teams. This proprietary platform is designed to augment the clinical expertise and experience of our salesforce. It is a tool that enhances how we connect science, clinical need and patient access in a more intelligent and scalable way,” stated Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma.
Designed as a continuous learning model, the AI platform adapts over time through ongoing integration of real-world U.S. claims data and marketing performance analytics. As new utilization trends and treatment behaviors emerge, the tool delivers predictive insights that enable dynamic content sequencing and tailored customer journeys across digital and in-person touchpoints.
By leveraging robust data analysis, experienced sales and marketing professionals, and machine learning, Citius Oncology is uniquely positioned to optimize its lean commercial infrastructure, accelerate healthcare provider education, and most importantly, enhance clinical decision-making and access to care for patients living with CTCL.
Health Technology Insights: Dried Plasma Innovation Addresses Critical Global Need
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- PR Newswire
